Zoliflodacin: a hope to treat antibiotic-resistant Neisseria gonorrhoeae  

作　　者：Snehal DDherange Aanya Verma Shivani Desai 

机构地区：[1]Department of Pharmacy Practice,Dr.D.Y.Patil Institute of Pharmaceutical Sciences and Research,Pimpri,Pune 411018,India

出　　处：《Infectious Diseases Research》2022年第2期18-23,共6页传染病研究（英文）

摘　　要：Background:Neisseria gonorrhoeae is a gram-negative diplococcus that leads to sexually transmitted infection.N.gonorrhoeae is an obligate human pathogen that causes infection to the mucus-secreting epithelial cells both in males and females.In 2017 the center for disease control and the World Health Organization published the list of global priority pathogens-12 with denting therapeutic options,including antibiotic-resistant N.gonorrhoeae.Methods:we thoroughly characterized zoliflodacin antibiotic,its clinical trials and effect on human health by using different keywords like“zoliflodacin”,“COVID-19”,“clinical trials”from different data sources like Pub-Med,Google-Scholar,and Science-Direct.Results:Zoliflodacin shows a therapeutic approach against N.gonorrhoeae.It acts by inhibiting bacterial type 2 topoisomerase with the binding sites in bacterial gyrase.It shows promising results against N.gonorrhoeae.Zoliflodacin is effective in treating gonococcal urogenital and rectal infection.Conclusion:Currently,antibiotic is the only option to treat N.gonorrhoeae with no vaccine available to treat it.The new drug,zoliflodacin,specifically targets antibiotic-resistant gonorrhea and it has given a hope to researchers.This review elaborates the discovery of zoliflodacin,its mechanism of action,current clinical trials,and its effectiveness.

关 键 词：Neisseria gonorrhoeae zoliflodacin COVID-19 ANTIBIOTIC-RESISTANCE TREATMENT 

分 类 号：R73[医药卫生—肿瘤]